You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Express Scripts
Dow
Mallinckrodt

Last Updated: October 3, 2023

Investigational Drug Information for Sulfatinib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Sulfatinib?

Sulfatinib is an investigational drug.

There have been 19 clinical trials for Sulfatinib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.

The most common disease conditions in clinical trials are Neuroendocrine Tumors, Neoplasms, and Carcinoid Tumor. The leading clinical trial sponsors are Hutchison Medipharma Limited, Fudan University, and BeiGene.

There are four US patents protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for Sulfatinib
TitleSponsorPhase
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerFudan UniversityPhase 1/Phase 2
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerShanghai Zhongshan HospitalPhase 1/Phase 2
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaChonnam National UniversityPhase 1/Phase 2

See all Sulfatinib clinical trials

Clinical Trial Summary for Sulfatinib

Top disease conditions for Sulfatinib
Top clinical trial sponsors for Sulfatinib

See all Sulfatinib clinical trials

US Patents for Sulfatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sulfatinib ⤷  Try a Trial Stable, concentrated radionuclide complex solutions ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) ⤷  Try a Trial
Sulfatinib ⤷  Try a Trial Stable, concentrated radionuclide complex solutions ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) ⤷  Try a Trial
Sulfatinib ⤷  Try a Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison MediPharma Limited (Shanghai, CN) ⤷  Try a Trial
Sulfatinib ⤷  Try a Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison Medipharma Limited (Shanghai, CN) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sulfatinib

Drugname Country Document Number Estimated Expiration Related US Patent
Sulfatinib Argentina AR119655 2038-07-25 ⤷  Try a Trial
Sulfatinib Australia AU2018433575 2038-07-25 ⤷  Try a Trial
Sulfatinib Australia AU2022203683 2038-07-25 ⤷  Try a Trial
Sulfatinib Brazil BR112021001148 2038-07-25 ⤷  Try a Trial
Sulfatinib Canada CA3153630 2038-07-25 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Express Scripts
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.